Clinical Benefit
| Substantial |
Le service médical rendu par cette spécialité est important dans le traitement au long cours des patients atteints du syndrome de Hunter (mucopolysaccharidose de type II).
|
Clinical Added Value
| important |
ELAPRASE, première thérapie de substitution enzymatique dans le traitement du syndrome de Hunter, apporte une amélioration du service médical rendu importante (ASMR II).
|
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
CgNrU6bau63eDKx9
